412 related articles for article (PubMed ID: 10507477)
1. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
[TBL] [Abstract][Full Text] [Related]
2. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
3. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
[TBL] [Abstract][Full Text] [Related]
5. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
[TBL] [Abstract][Full Text] [Related]
6. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of five humanized OKT3 effector function variant antibodies.
Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA
Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879
[TBL] [Abstract][Full Text] [Related]
8. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
9. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.
Meijer RT; Surachno S; Yong SL; Bemelman FJ; Florquin S; Ten Berge IJ; Schellekens PT
Clin Exp Immunol; 2003 Sep; 133(3):485-92. PubMed ID: 12930378
[TBL] [Abstract][Full Text] [Related]
12. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
13. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
[TBL] [Abstract][Full Text] [Related]
16. [OKT3 treatment of refractory renal allograft rejection].
Xu J; Ma J; Bai X
Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
[TBL] [Abstract][Full Text] [Related]
17. OKT3 treatment of cardiac allograft rejection.
Haverty TP; Sanders M; Sheahan M
J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
[TBL] [Abstract][Full Text] [Related]
18. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
19. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of rejection after simultaneous pancreas-kidney transplantation.
Yang L; Liu YF; Liu SR; Wu G; Zhang JL; Meng YM; Shong SW; Li GC
Chin Med Sci J; 2005 Sep; 20(3):210-3. PubMed ID: 16261897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]